Luca Quagliata, PhD, BCMAS, COA, is the vice president and global head of medical affairs for Thermo Fisher's Clinical Sequencing and Oncology Division. Quagliata is trained in medical biotechnology, holds a PhD in vascular medicine, and is a board certified medical affairs specialist. Prior to joining Thermo Fisher, he was senior director for the R&D Unit and leader of the Molecular Diagnostics Division, University Hospital Basel, Switzerland. With the goal of enabling precision medicine, Quagliata’s team was among the first in Europe to introduce NGS into routine diagnostics of solid tumors.
Articles by Luca Quagliata, PhD, BCMAS, COA
|5 min read
Molecular Pathology Will Lean Further into Liquid Biopsy and Proteomics in 2026
Thermo Fisher’s Luca Quagliata also discusses pathologists’ desire for rapid turnaround times
|2 min read
Rapid In-House NGS Is Closing the Gap in Precision Cancer Therapy
Automated NGS reduces complexity and cost, enabling community hospitals to expand testing without major infrastructure investmentsPage 1 of 1
